Literature DB >> 23550626

Decreased Nox4 levels in the myocardium of patients with aortic valve stenosis.

María U Moreno1, Idoia Gallego, Begoña López, Arantxa González, Ana Fortuño, Gorka San José, Félix Valencia, Juan José Gómez-Doblas, Eduardo de Teresa, Ajay M Shah, Javier Díez, Guillermo Zalba.   

Abstract

The NADPH oxidases are a key family of ROS (reactive oxygen species)-producing enzymes which may differentially contribute to cardiac pathophysiology. Animal studies show uncertain results regarding the regulation of cardiac Nox4 by pressure overload and no data are available on human myocardial Nox4. In the present study, we evaluated Nox4 expression and its relationship with myocardial remodelling and LV (left ventricular) function in patients with severe AS (aortic valve stenosis). Endomyocardial biopsies from 34 patients with AS were obtained during aortic valve replacement surgery. LV morphology and function were assessed by echocardiography. Myocardial samples from subjects deceased of non-CVDs (cardiovascular diseases) were analysed as controls. Nox4 localization was evaluated by immunohistochemistry and quantified by Western blot. Myocardial capillary density, fibrosis and cardiomyocyte dimensions and apoptosis were assessed histologically to evaluate myocardial remodelling. Nox4 was present in samples from all subjects and expressed in cardiomyocytes, VSMCs (vascular smooth muscle cells), endothelium and fibroblasts. Nox4 levels were reduced 5-fold in AS patients compared with controls (P<0.01). Nox4 levels directly correlated with cardiomyocyte cross-sectional area (r=0.299, P<0.05) and diameter (r=0.406, P<0.05) and capillary density (r=0.389, P<0.05), and inversely with cardiomyocyte apoptosis (r=-0.316, P<0.05) in AS patients. In addition, Nox4 levels correlated with echocardiographic parameters (LV ejection fraction: r=0.353, P<0.05; midwall fractional shortening: r=0.355, P<0.05; deceleration time: r=-0.345, P<0.05) in AS patients. Nox4 is expressed in human myocardium and reduced in AS patients. The observed associations of Nox4 with cardiomyocyte parameters and capillary density in AS patients suggest a potential role of Nox4 deficiency in the myocardial remodelling present in the human pressure-overloaded heart.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23550626     DOI: 10.1042/CS20120612

Source DB:  PubMed          Journal:  Clin Sci (Lond)        ISSN: 0143-5221            Impact factor:   6.124


  5 in total

Review 1.  Polymerase δ-interacting Protein 2: A Multifunctional Protein.

Authors:  Marina S Hernandes; Bernard Lassègue; Kathy K Griendling
Journal:  J Cardiovasc Pharmacol       Date:  2017-06       Impact factor: 3.105

2.  Cardiac and renal upregulation of Nox2 and NF-κB and repression of Nox4 and Nrf2 in season- and diabetes-mediated models of vascular oxidative stress in guinea-pig and rat.

Authors:  Anna Gajos-Draus; Monika Duda; Andrzej Beręsewicz
Journal:  Physiol Rep       Date:  2017-10-29

3.  Reappraising myocardial fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients.

Authors:  Thomas A Treibel; Begoña López; Arantxa González; Katia Menacho; Rebecca S Schofield; Susana Ravassa; Marianna Fontana; Steven K White; Carmelo DiSalvo; Neil Roberts; Michael T Ashworth; Javier Díez; James C Moon
Journal:  Eur Heart J       Date:  2018-02-21       Impact factor: 29.983

4.  Methylation-dependent antioxidant-redox imbalance regulates hypertensive kidney injury in aging.

Authors:  Sathnur Pushpakumar; Lu Ren; Subir Kumar Juin; Suravi Majumder; Rohan Kulkarni; Utpal Sen
Journal:  Redox Biol       Date:  2020-10-10       Impact factor: 11.799

5.  Poldip2 mediates blood-brain barrier disruption and cerebral edema by inducing AQP4 polarity loss in mouse bacterial meningitis model.

Authors:  Meng Gao; Weitian Lu; Yue Shu; Zhengyu Yang; Shanquan Sun; Jin Xu; Shengwei Gan; Shujuan Zhu; Guoping Qiu; Fei Zhuo; Shiye Xu; Yiying Wang; Junhong Chen; Xuan Wu; Juan Huang
Journal:  CNS Neurosci Ther       Date:  2020-08-12       Impact factor: 5.243

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.